Skip to main content
Sharp Therapeutics Corp. logo

Sharp Therapeutics Corp. — Investor Relations & Filings

Ticker · SHRX ISIN · CA8200092077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 128 across all filing types
Latest filing 2026-04-17 Regulatory Filings
Country CA Canada
Listing TSXV SHRX

About Sharp Therapeutics Corp.

https://sharptx.com/

Sharp Therapeutics Corp. is a preclinical-stage drug discovery company developing small molecule therapeutics for hereditary disorders. The core business involves leveraging its proprietary Disco(tm) platform, which integrates high-speed laboratory automation with advanced computational methods, including molecular-physics and mathematical modeling, to rapidly identify small molecules that correct protein defects. This approach is designed to deliver first-choice oral medicines for genetic diseases, offering advantages over traditional biologics. Sharp focuses on monogenic diseases to utilize an accelerated and de-risked clinical development path. Current lead programs address high unmet needs in Gaucher Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C.

Recent filings

Filing Released Lang Actions
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a Canadian securities regulatory form (Form 13-501F1) for participation fee management certification submitted to the Alberta Securities Commission. It is not announcing or providing financial results, nor is it an AGM presentation, earnings release, or other specific report category. This is a general regulatory filing and thus falls under the fallback category Regulatory Filings (RNS).
2026-04-17 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is Form 13-502F1, a participation fee form filed with the Ontario Securities Commission under OSC Rule 13-502 Fees. It details quarterly market values, calculation of participation fees, and includes management certification. It is neither an annual or quarterly financial report nor an earnings release, dividend notice, or board change notice. This is a regulatory filing to satisfy fees under securities rules, so it should be classified in the fallback Regulatory Filings category (RNS).
2026-04-17 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a regulatory form (Form 13-501F1) filed with the Alberta Securities Commission, detailing a participation fee calculation and management certification. It is not an annual or quarterly financial report, earnings release, governance statement, or investor presentation, but rather a mandatory regulatory submission. This falls under the generic ‘Regulatory Filings’ category.
2026-04-17 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document consists of the Independent Auditor’s Report and the full set of audited consolidated financial statements (statements of financial position, loss and comprehensive loss, cash flows, changes in equity, and accompanying notes) for the years ended December 31, 2025 and December 31, 2024. It does not include broader narrative sections typical of a complete annual report (e.g., full MD&A, business overview, risk factors) but is focused on the audited financial statements and auditor’s opinion. This aligns with the definition of a standalone Audit Report / Information filing (AR). FY 2025
2026-04-17 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document is a set of audited consolidated financial statements including an Independent Auditor’s Report, balance sheet, income statement, cash flows, and notes for the years ended December 31, 2025 and 2024. It does not contain the broader narrative, business review or corporate details typical of a full Annual Report (10-K), nor is it a short publication announcement. Instead, it is the standalone audited financial statements and auditor’s opinion, fitting the definition of an Audit Report / Information (AR). FY 2025
2026-04-17 English
Report of Distributions outside Canada (Form 72-503F).pdf
Regulatory Filings Classification · 1% confidence The document is a prescribed regulatory form (Form 72-503F) filed under Canadian securities legislation to report distributions of securities (convertible notes) outside Canada. It is not an annual or interim report, earnings release, management discussion, nor a simple announcement of a report. It is a mandatory regulatory filing that does not fit any more specific category, so it falls under the generic Regulatory Filings category.
2026-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.